Krysiak Robert, Kowalcze Karolina, Ott Johannes, Deledda Andrea, Okopień Bogusław
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland.
Department of Pediatrics in Bytom, Faculty of Health Sciences in Katowice, Medical University of Silesia, Stefana Batorego 15, 41-902 Bytom, Poland.
Nutrients. 2025 May 27;17(11):1813. doi: 10.3390/nu17111813.
: Although untreated prolactin excess is often associated with female sexual dysfunction, sexual functioning improves after chronic administration of dopamine agonists, including cabergoline. Extra-sexual benefits of cabergoline therapy were found to be less pronounced in young hyperprolactinemic women in the case of coexistent hypovitaminosis D. Thus, the present study was aimed at investigating whether vitamin D status also determines cabergoline action on sexual function and depressive symptoms in reproductive-age women. : This prospective cohort study included 75 young women with prolactin excess, who, depending on vitamin D status, were assigned to one of three groups. Females with vitamin D deficiency (group A), vitamin D-insufficient women (group B) and vitamin D-sufficient women (group C) were matched for age, body mass index, blood pressure and prolactin levels. For the following six months, they received cabergoline. Before and after cabergoline treatment, all participants completed questionnaires evaluating female sexual functioning (FSFI) and depressive symptoms (BMI-II). The remaining outcomes of interest included plasma levels of 25-hydroxyvitamin D, prolactin and sex hormones. : Before treatment, there were no differences between the study groups in sexual functioning and mood. The study groups differed in post-treatment levels of 25-hydroxyvitamin D, prolactin, testosterone and estradiol. Although cabergoline reduced the total FSFI score and improved functioning in all domains of the FSFI questionnaire, this effect was strongest in group C and weakest in group A. Statistically significant changes in the BDI-II score were observed only in group C. The increase in the total FSFI score and domain scores correlated with the decrease in prolactin levels, 25-hydroxyvitamin D levels, the increase in testosterone and estradiol concentrations, and the reduction in the BDI-II score. Low vitamin D status attenuates the beneficial effects of cabergoline on sexual function and depressive symptoms in reproductive-age women.
虽然未经治疗的高催乳素血症常与女性性功能障碍有关，但长期服用多巴胺激动剂（包括卡麦角林）后性功能会有所改善。在同时存在维生素D缺乏症的年轻高催乳素血症女性中，卡麦角林治疗的性外益处并不那么明显。因此，本研究旨在调查维生素D状态是否也决定卡麦角林对育龄女性性功能和抑郁症状的作用。 这项前瞻性队列研究纳入了75名高催乳素血症的年轻女性，根据维生素D状态，她们被分为三组。维生素D缺乏的女性（A组）、维生素D不足的女性（B组）和维生素D充足的女性（C组）在年龄、体重指数、血压和催乳素水平方面进行了匹配。在接下来的六个月里，她们接受卡麦角林治疗。在卡麦角林治疗前后，所有参与者都完成了评估女性性功能（FSFI）和抑郁症状（BDI-II）的问卷。其他感兴趣的结果包括血浆25-羟维生素D、催乳素和性激素水平。 治疗前，研究组在性功能和情绪方面没有差异。研究组在治疗后的25-羟维生素D、催乳素、睾酮和雌二醇水平上有所不同。虽然卡麦角林降低了FSFI总分，并改善了FSFI问卷所有领域的功能，但这种效果在C组最强，在A组最弱。仅在C组观察到BDI-II评分有统计学意义的变化。FSFI总分和各领域评分的增加与催乳素水平、25-羟维生素D水平的降低、睾酮和雌二醇浓度的增加以及BDI-II评分的降低相关。低维生素D状态会减弱卡麦角林对育龄女性性功能和抑郁症状的有益作用。
